throbber
HIGHLIGHTS OF PRESCRIBING INFORMATION
`These highlights do not include all the information needed to use CINRYZE®
`safely and effectively. See full prescribing information for CINRYZE.
`CINRYZE® (C1 Esterase Inhibitor [Human])
`For Intravenous Use, Freeze-Dried Powder for Reconstitution
`Initial U.S. Approval: 2008
`RECENT MAJOR CHANGES
`INDICATIONS AND USAGE
`CINRYZE is a C1 esterase inhibitor indicated for routine prophylaxis against angioedema
`attacks in adolescent and adult patients with Hereditary Angioedema (HAE).
`DOSAGE AND ADMINISTRATION
`• Intravenous Use Only
`• Prior to reconstitution, protect from light.
`• A silicone-free syringe is recommended
`• Store at 2 C - 25 C (36 F - 77 F). Do not freeze.
`• To obtain the required dose, reconstitute two CINRYZE vials with two vials Sterile
`Water for Injection, USP (5 mL each) using aseptic sterile technique.
`• Administer at room temperature within 3 hours of reconstitution.
`
`Routine Prophylaxis Dosing
`
`Indication
`
`Dose
`
` Infusion rate
`
`1 mL/min
`(10 min)
`
`1,000 Units Intravenous
`Routine prophylaxis
`every 3 or 4 days
`against HAE attacks
`DOSAGE FORMS AND STRENGTHS
`Approximately 500 Units (lyophilized) in an 8 mL vial.
`CONTRAINDICATIONS
`Patients who have manifested life-threatening immediate hypersensitivity reactions,
`including anaphylaxis, to the product (4).
`WARNINGS/PRECAUTIONS
`• Hypersensitivity reactions may occur. Have epinephrine immediately available
`for treatment of acute severe hypersensitivity reaction (5.1).
`• Thrombotic events have been reported in patients receiving CINRYZE for routine
`prophylaxis. Thrombotic events also have been reported in patients receiving off-label
`high dose C1 esterase inhibitor therapy (5.2). Monitor closely patients with known risk
`factors for thrombotic events.
`
`• CINRYZE is made from human plasma and may contain infectious agents, e.g.
`viruses and, theoretically, the Creutzfeldt-Jakob disease agent. (5.3)
`ADVERSE REACTIONS
`The most common adverse reactions observed were headache, nausea, rash, and
`vomiting. (5.1, 6.1)
`To report SUSPECTED ADVERSE REACTIONS, contact ViroPharma Medical
`Information at (866) 331-5637 or the FDA at 1-800-FDA-1088 or
`www.fda.gov/medwatch.
`
`USE IN SPECIFIC POPULATIONS
`Pregnancy: No human or animal data. Use only if clearly needed. (8.1)
`
`See 17 for PATIENT COUNSELING INFORMATION and FDA-approved
`patient labeling.
`
`Revised: November 2012
`
`FULL PRESCRIBING INFORMATION: CONTENTS*
`1 INDICATIONS AND USAGE
`2 DOSAGE AND ADMINISTRATION
`2.1 Routine Prophylaxis against HAE attacks
`2.2 Instructions for use
`2.3 Preparation and Handling
`2.4 Administration
`3 DOSAGE FORMS AND STRENGTHS
`4 CONTRAINDICATIONS
`5 WARNINGS AND PRECAUTIONS
`5.1 Hypersensitivity Reactions
`5.2 Thrombotic Events
`5.3 Transmissible Infectious Agents
`
`FULL PRESCRIBING INFORMATION
`CINRYZE® (C1 Esterase Inhibitor [Human])
`Freeze-Dried Powder for Reconstitution
`1 INDICATIONS AND USAGE
`CINRYZE is a C1 esterase inhibitor indicated for routine prophylaxis against angioedema
`attacks in adolescent and adult patients with Hereditary Angioedema (HAE).
`2 DOSAGE AND ADMINISTRATION
`For Intravenous Use Only.
`2.1 Routine prophylaxis against HAE Attacks
`• A dose of 1,000 Units CINRYZE can be administered every 3 or 4 days for routine
`prophylaxis against angioedema attacks in HAE patients.
`• CINRYZE is administered at an injection rate of 1 mL per minute.
`Table 1
`Routine Prophylaxis Dosing
`
`Indication
`
`Dose
`
`Infusion rate
`
`1 mL/min
`(10 min)
`
`1,000 Units Intravenous
`every 3 or 4 days
`
`Routine prophylaxis
`against HAE attacks
`2.2 Instructions for Use
`The procedures below are provided as general guidelines for the reconstitution and
`administration of CINRYZE. Use either the Mix2Vial® transfer device or a
`commercially available double-ended needle.
`Always work on a clean surface and wash your hands before performing the
`following procedures.
`Reconstitution, product administration, and handling of the administration set and needles
`must be done with caution. Percutaneous puncture with a needle contaminated with blood
`can transmit infectious viruses including HIV (AIDS) and hepatitis. Obtain immediate
`medical attention if injury occurs. Place needles in a sharps container after single use.
`Discard all equipment, including any reconstituted CINRYZE in an appropriate container.
`2.3 Preparation and Handling
`• Protect CINRYZE from light prior to reconstitution.
`• A silicone-free syringe is recommended for reconstitution and administration
` of CINRYZE.
`• Inspect the reconstituted product for particulate matter prior to administration; do
`not use if particles are observed or if solution is turbid. The reconstituted solution is
`colorless to slightly blue.
`• Each vial of CINRYZE is for single use only. Promptly use any vial that has been
`entered and discard partially used vials in accordance with biohazard procedures.
`CINRYZE contains no preservative.
`• Do not mix CINRYZE with other materials.
`• Do not use if frozen.
`• Do not use after expiration date.
`Reconstitution:
`Two vials of reconstituted CINRYZE are combined for a single dose. Sterile
`Water for Injection, USP, is required and not supplied with CINRYZE.
`1. Aseptic technique should be used during the reconstitution procedure.
`2. Bring the CINRYZE (powder) and Sterile Water for Injection, USP (diluent) (not
`supplied) to room temperature if refrigerated.
`3. Remove caps from the CINRYZE and diluent vials.
`4. Cleanse stoppers with an alcohol wipe or swab, and allow them to dry prior to use.
`5. Remove protective covering from the top of the Mix2Vial transfer device package.
`Do not remove the device from the package.
`6. Note: Diluent vial must be accessed prior to the vial of CINRYZE to prevent loss
`of vacuum. Place diluent on a flat surface and insert the blue end of the device into
`the diluent vial, pushing down until the spike penetrates through the center of the
`diluent vial stopper and the device snaps in place (Figure 1). The Mix2Vial transfer
`device must be positioned completely vertical prior to penetrating the stopper closure.
`7. Remove the plastic package and discard it (Figure 2). Take care not to touch the
`exposed end of the device.
`8. Place vial of CINRYZE on a flat surface. Invert diluent vial containing 5 mL Sterile
`Water for Injection, USP, and insert the clear end into the CINRYZE vial, pushing
`down until the spike penetrates the rubber stopper and the device snaps into place. The
`Mix2Vial transfer device must be positioned completely vertical prior to penetrating
`the stopper closure. The Sterile Water for Injection, USP will automatically flow
`into the vial of CINRYZE (Figure 3), because the vacuum in the vial will draw in
`the diluent. If there is no vacuum in the vial, do not use the product.
`9. Gently swirl (do not shake) the CINRYZE vial until all powder is dissolved. Be
`sure that CINRYZE is completely dissolved (Figure 4). Disconnect the Sterile
`Water for Injection, USP vial by turning it counterclockwise (Figure 5). Do not
`remove the clear end of the Mix2Vial transfer device from the vial of CINRYZE.
`One vial of reconstituted CINRYZE contains 5 mL of C1 esterase inhibitor at a
`concentration of 100 Units/mL. Reconstitute two vials of CINRYZE for one dose. Repeat
`steps 1 to 9 above using an additional package containing a Mix2Vial transfer
`device to reconstitute the second of two vials of CINRYZE. Do not reuse the
`Mix2Vial transfer device. CINRYZE must be administered at room temperature within
`3 hours after reconstitution.
`
`Figure 1
`
`Figure 2
`
`Figure 3
`
`Figure 5
`
`Figure 4
`2.4 Administration
`Two vials of reconstituted CINRYZE are combined for a single dose.
`1. Use Aseptic Technique.
`2. After reconstitution, the solution should be clear with no evidence of turbidity.
`Reconstituted solution should be colorless to slightly blue. Do not use if solution
`is turbid or otherwise discolored.
`3. Please refer to the illustrations in steps 7 to 9 included within the Patient
`Information Leaflet. Utilizing a sterile, disposable 10 mL syringe, draw back
`the plunger to admit 5 mL air into the syringe.
`4. Attach the syringe onto the top of the clear end of the Mix2Vial transfer device by
`turning it clockwise.
`5. Invert the vial and inject air into the solution and then slowly withdraw the
`reconstituted CINRYZE into the syringe.
`6. Detach the syringe from the vial by turning it counterclockwise and releasing it
`from the clear end of the Mix2Vial transfer device.
`7. Using the same syringe, repeat steps 3 to 6 with a second vial of CINRYZE to
`make the complete dose. CINRYZE should be administered promptly after
`preparation in the syringe and should not be used if particles are observed
`or if the solution is turbid.
`
`6 ADVERSE REACTIONS
`6.1 Clinical Trials Experience
`6.2 Postmarketing Experience
`7 DRUG INTERACTIONS
`8 USE IN SPECIFIC POPULATIONS
`8.1 Pregnancy
`8.2 Labor and Delivery
`8.3 Nursing Mothers
`8.4 Pediatric Use
`8.5 Geriatric Use
`10 OVERDOSAGE
`11 DESCRIPTION
`
`8. Attach a suitable needle or infusion set with winged adapter, and inject
`intravenously. As a guideline, administer 1,000 Units (reconstituted in 10 mL) of
`CINRYZE by intravenous injection at a rate of 1 mL per minute over 10 minutes.
`(See DOSAGE AND ADMINISTRATION [2]) Please refer to the illustration in step
`3 of the self administration section within the Patient Information Leaflet.
`9. Dispose of all unused solution, the empty vial(s), and the used needles and
`syringes in an appropriate container for throwing away waste that might hurt
`others if not handled properly.
`3 DOSAGE FORMS AND STRENGTHS
`• CINRYZE (Freeze-Dried powder for Reconstitution) is a lyophilized preparation
`available in a single-use vial that contains 500 Units (U) human C1 esterase inhibitor.
`• Each vial must be reconstituted with 5 mL Sterile Water for Injection, USP (diluent)
`(not supplied).
`• Two reconstituted vials must be used to make a single, 1,000 Units, dose.
`4 CONTRAINDICATIONS
`CINRYZE is contraindicated in patients who have manifested life-threatening
`immediate hypersensitivity reactions, including anaphylaxis to the product.
`5 WARNINGS AND PRECAUTIONS
`5.1 Hypersensitivity Reactions
`Severe hypersensitivity reactions may occur. The signs and symptoms of
`hypersensitivity reactions may include the appearance of hives, urticaria, tightness of the
`chest, wheezing, hypotension and/or anaphylaxis experienced during or after injection
`of CINRYZE.
`Consider treatment methods carefully, because hypersensitivity reactions may have
`symptoms similar to HAE attacks.
`In case of hypersensitivity, discontinue CINRYZE infusion and institute appropriate
`treatment. Have epinephrine immediately available for treatment of acute severe
`hypersensitivity reaction. (See Patient Counseling Information [17])
`5.2 Thrombotic Events
`Thrombotic events have been reported following administration of C1 esterase inhibitor
`products when used off-label at high doses.2 Animal studies have supported a concern
`about the risk of thrombosis from intravenous administration of C1 esterase inhibitor
`products.3 (See Sections 10 OVERDOSAGE and 13.2 Animal Toxicology and/or
`Pharmacology)
`In an open-label trial further investigating the use of CINRYZE for prevention
`(n=146) of HAE attacks, 5 serious thrombotic events (including myocardial
`infarction, deep vein thrombosis, pulmonary embolism and 2 events of
`cerebrovascular accident) occurred. Subjects had underlying risk factors for
`thrombotic events. Monitor closely patients with known risk factors for thrombotic
`events.
`5.3 Transmissible Infectious Agents
`Because CINRYZE is made from human blood, it may carry a risk of transmitting
`infectious agents, e.g. viruses, and, theoretically, the Creutzfeldt-Jakob disease (CJD)
`agent [11]. ALL infections thought by a physician possibly to have been transmitted
`by CINRYZE should be reported by the physician or other healthcare provider to
`ViroPharma Medical Information [(866) 331-5637]. The physician should discuss
`the risks and benefits of this product with the patient, before prescribing or
`administering it to the patient. (See Patient Counseling Information [17])
`6 ADVERSE REACTIONS
`The only serious adverse reaction observed in clinical studies of CINRYZE was
`cerebrovascular accident.
`The most common adverse reactions observed were headache, nausea, rash, and
`vomiting.
`Because CINRYZE is a therapeutic protein, there is potential for immunogenicity.
`Using a validated assay there was no evidence of antibody development following
`administration of CINRYZE. The detection of antibody formation is highly
`dependent on the sensitivity and specificity of the assay. Additionally, the observed
`incidence of anti-C1 Esterase Inhibitor antibody positivity in an assay may be
`influenced by several factors including assay methodology, sample handling, timing
`of sample collection, concomitant medications, and underlying disease. For these
`reasons, comparison of the incidence of antibody development across products
`cannot be made.
`6.1 Clinical Trials Experience
`Because clinical studies are conducted under widely varying conditions, adverse reaction
`rates observed in the clinical trials of a drug cannot be directly compared to rates in the
`clinical trials of another drug and may not reflect the rates observed in practice.
`Routine Prophylaxis
`Twenty-four subjects were evaluated in the randomized, placebo-controlled,
`crossover, routine prophylaxis trial.
`There were no serious adverse reactions in the randomized, placebo-controlled,
`crossover, routine prophylaxis trial.
`Adverse reactions in the randomized, placebo-controlled, crossover, routine
`prophylaxis trial (n=24) that occurred in at least two subjects (≥8%) receiving
`CINRYZE are given in the following table:
`Table 2 Adverse Reactions in the Randomized, Placebo-Controlled,
`Crossover, Routine Prophylaxis Trial
`Number of
`Number of
`Adverse Reaction
`Subjects (N = 24)
`Adverse Reactions
`5
`8
`Rash
`4
`4
`Headache
`2
`2
`Pruritus
`2
`2
`Vomiting
`In an open-label follow-on trial, 146 patients received a median of 243.5 days of
`CINRYZE (maximum = 959 days). The most common adverse reaction observed
`was headache. No patients were discontinued due to an adverse reaction.
`Adverse reactions in the open-label follow-on trial (n=146) that occurred in at least
`three subjects (≥2%) receiving CINRYZE, are given in the following table:
`Table 3 Adverse Reactions in the Open-Label Follow-On Trial
`Number (%) of
`Number (%) of
`Infusion Days
`Subjects (N=146)
`(N=11,435) with
`with Adverse
`Adverse Reaction
`Reaction
`28 (19)
`62 (0.5)
`Headache
`26 (18)
`29 (0.3)
`Nausea
`15 (10)
`30 (0.3)
`Rash
`15 (10)
`17 (0.1)
`Vomiting
`7 (5)
`7 (<0.1)
`Pyrexia
`4 (3)
`5 (<0.1)
`Catheter Site Pain
`3 (2)
`4 (<0.1)
`Dizziness
`3 (2)
`3 (<0.1)
`Erythema
`3 (2)
`4 (<0.1)
`Pruritus
`More than 14,000 doses of CINRYZE have been administered to over 260 different
`patients in all completed, controlled and open-label clinical studies. All patients who
`were evaluated were found negative for seroconversion to parvovirus B19, Hepatitis
`B, Hepatitis C and HIV. (See Section 5 3 Transmissible Infectious Agents)
`
`Adverse Reaction
`
`12 CLINICAL PHARMACOLOGY
`12.1 Mechanism of Action
`12.2 Pharmacodynamics
`12.3 Pharmacokinetics
`13 NONCLINICAL TOXICOLOGY
`13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
`13.2 Animal Toxicology and/or Pharmacology
`14 CLINICAL STUDIES
`15 REFERENCES
`16 HOW SUPPLIED/STORAGE AND HANDLING
`17 PATIENT COUNSELING INFORMATION
`*Sections or subsections omitted from the full prescribing information are not listed
`
`6.2 Postmarketing Experience
`Because postmarketing reporting of adverse reactions is voluntary and from a
`population of uncertain size, it is not always possible to reliably estimate the
`frequency of these reactions or establish a causal relationship to product exposure.
`Postmarketing adverse reactions include local infusion site reactions (including
`inflammation or hematoma at the infusion site).
`Postmarketing thrombotic events have been reported, including catheter-related and
`deep venous thromboses, transient ischemic attack, and stroke.
`7 DRUG INTERACTIONS
`No drug interaction studies have been conducted.
`8 USE IN SPECIFIC POPULATIONS
`8.1 Pregnancy
`Pregnancy Category C. No animal data are available. No adequate and well-controlled
`studies were conducted in pregnant women. It is not known whether CINRYZE can
`cause fetal harm when administered to a pregnant woman or can affect reproduction
`capacity. CINRYZE should be given to a pregnant woman only if clearly needed.
`8.2 Labor and Delivery
`The safety and effectiveness of CINRYZE administration prior to or during labor and
`delivery have not been established. Use only if clearly needed.
`8.3 Nursing Mothers
`It is not known whether CINRYZE is excreted in human milk. Because many
`drugs are excreted in human milk, caution should be exercised when CINRYZE
`is administered to a nursing woman.
`8.4 Pediatric Use
`The safety and effectiveness of CINRYZE have not been established in neonates,
`infants, or children. Three of the 24 subjects in the randomized, placebo-controlled,
`crossover, routine prophylaxis trial, were under the age of 18 years (9, 14, and 16
`years of age).
`8.5 Geriatric Use
`The randomized, placebo-controlled, crossover, routine prophylaxis trial did not include
`sufficient numbers of subjects 65 years of age and older to determine whether they
`respond differently from younger subjects.
`10 OVERDOSAGE
`The maximum dose administered in clinical studies was 4000 Units given over
`approximately 5 hours (an average dose of 57 Units/kg) and 9000 Units given over a 7 day
`period. There have been no overdosages of CINRYZE reported during clinical studies.
`In vitro and in vivo animal thrombogenicity studies with CINRYZE showed a
`potential for clot formation when CINRYZE was administered at doses 14 times the
`recommended clinical dose (greater than 200U/kg). Thrombotic events have been
`reported with another C1 esterase inhibitor product when used off-label at high
`doses.2 Animal studies have supported a concern about the risk of thrombosis from
`intravenous administration of C1 esterase inhibitor products.3 (See Section 13.2
`Animal Toxicology and/or Pharmacology and Section 5.2 Thrombotic events in
`WARNINGS AND PRECAUTIONS)
`11 DESCRIPTION
`CINRYZE (C1 esterase inhibitor [human]) (Freeze-Dried powder for Reconstitution)
`is a sterile, stable, lyophilized preparation of C1 esterase inhibitor derived from
`human plasma. CINRYZE is manufactured from human plasma purified by a
`combination of filtration and chromatographic procedures. The specific activity
`of CINRYZE is 4.0 – 9.0 units/mg protein. The purity is ≥ 90% human C1 esterase
`inhibitor. Following reconstitution with 5 mL of Sterile Water for Injection, USP,
`each vial contains approximately 500 units of functionally active C1 esterase
`inhibitor, pH 6.6 - 7.4, and an osmolality between 200 – 400 mosmol/kg. One Unit
`(U) of CINRYZE corresponds to the mean quantity of C1 esterase inhibitor present
`in 1 mL of normal fresh plasma.
`CINRYZE, when reconstituted with 5 mL of Sterile Water for Injection, USP contains
`the following excipients: 4.1 mg/mL sodium chloride, 21 mg/mL sucrose, 2.6 mg/mL
`trisodium citrate, 2.0 mg/mL L-Valine, 1.2 mg/mL L-Alanine, and 4.5 mg/mL L-Threonine.
`The following manufacturing steps are designed to reduce the risk of viral transmission:
`• Screening donors at U.S. licensed blood collection centers to rule out infection with
`Human Immunodeficiency Virus (HIV-1/HIV-2), Hepatitis B Virus, or Hepatitis C Virus.
`• Testing plasma pools by in-process NAT for parvovirus B19 via minipool testing and the
`limit of B19 in the manufacturing pool is set not to exceed 104 IU of B19 DNA per mL.
`• Use of two independent viral reduction steps in the manufacture of CINRYZE:
`pasteurization (heat treatment at 60 C for 10 hours in solution with stabilizers) and
`nanofiltration through two sequential 15 nm filters.
`These viral reduction steps, along with a step in the manufacturing process, PEG
`precipitation, have been validated in a series of in vitro experiments for their capacity
`to inactivate/remove a wide range of viruses of diverse physicochemical
`characteristics including: Human Immunodeficiency Virus (HIV), Hepatitis A Virus
`(HAV), and the following model viruses: Bovine Viral Diarrhea Virus (BVDV) as a
`model virus for HCV, Canine Parvovirus (CPV) as a model virus for Parvovirus B19,
`Pseudorabies Virus (PRV) as a model virus for large enveloped DNA viruses (e.g.
`herpes virus). Total mean log10 reductions are shown in Table 4.
`Table 4
`Log10 Virus Reduction Factor for Selected Viruses
`Log10 Virus Reduction
`Enveloped viruses
`Non-enveloped viruses
`PRV
`BVDV
`HAV
`CPV
`HIV
`PEG
`6.0 ± 0.3
`4.5 ± 0.3
`2.8 ± 0.2
`4.2 ± 0.2
`5.1 ± 0.2
`precipitation
`Pasteurization > 6.1 ± 0.2 > 6.7 ± 0.3 > 6.7 ± 0.2
`2.8 ± 0.3
`0.1 ± 0.3
`Nanofiltration > 5.6 ± 0.2 > 5.5 ± 0.2 > 6.4 ± 0.3 > 4.9 ± 0.2 > 4.5 ± 0.3
`Total
`> 16.8
`> 16.7
`> 19.1
`> 10.5
`> 8.7
`reduction
`12 CLINICAL PHARMACOLOGY
`12.1 Mechanism of Action
`C1 inhibitor is a normal constituent of human blood and is one of the serine proteinase
`inhibitors (serpins). The primary function of C1 inhibitor is to regulate the activation
`of the complement and intrinsic coagulation (contact system) pathway. C1 inhibitor
`also regulates the fibrinolytic system. Regulation of these systems is performed
`through the formation of complexes between the proteinases and the inhibitor,
`resulting in inactivation of both and consumption of the C1 inhibitor.
`HAE patients have low levels of endogenous or functional C1 inhibitor. Although
`the events that induce attacks of angioedema in HAE patients are not well defined, it
`is thought by some that increased vascular permeability and the clinical manifestation
`of HAE attacks are primarily mediated through contact system activation. Suppression
`of contact system activation by C1 inhibitor through the inactivation of plasma
`kallikrein and factor XIIa is thought to modulate this vascular permeability by
`preventing the generation of bradykinin.1 Administration of CINRYZE increases
`plasma levels of C1 inhibitor activity.
`12.2 Pharmacodynamics
`In clinical studies, the intravenous administration of CINRYZE demonstrated an increase
`in plasma levels of C1 inhibitor within approximately one hour or less of administration.
`Biological activity of CINRYZE was shown in 35 subjects by the subsequent
`increase in plasma C4 levels from an average of C4 8.1 mg/mL at baseline to C4
`8.6 mg/mL 12 hours after infusion of CINRYZE.
`
`Process step
`
`CSL EXHIBIT 1010
`CSL v. Shire
`
`Page 1 of 2
`
`

`

`12.3 Pharmacokinetics
`A randomized, parallel group, open-label pharmacokinetics (PK) study of CINRYZE
`was performed in patients with non-symptomatic hereditary angioedema (HAE).
`The patients received either a single dose of 1,000 Units or 1,000 Units followed by
`a second 1,000 Units 60 minutes later. The PK results for functional C1 inhibitor are
`presented in the following table:
`Table 5 Mean pharmacokinetic parameters of Functional C1 Inhibitor
`Parameters
`Single Dose
`Double Dose
`Cbaseline (units/mL)
`0.31 ± 0.20 (n = 12)
`0.33 ± 0.20 (n = 12)
`Cmax (units/mL)
`0.68 ± 0.08 (n = 12)
`0.85 ± 0.12 (n = 13)
`Tmax (hrs)
`3.9 ± 7.3 (n = 12)
`2.7 ± 1.9 (n = 13)
`AUC(0-t) (units*hr/mL)
`74.5 ± 30.3 (n = 12)
`95.9 ± 19.6 (n = 13)
`CL (mL/min)
`0.85 ± 1.07 (n = 7)
`1.17 ± 0.78 (n = 9)
`Half-life (hours)
`56 ± 36 (n = 7)
`62 ± 38 (n = 9)
`Numbers in parentheses are number of subjects evaluated
`Single dose = 1,000 Units
`Double dose = 1,000 Units followed by a second 1,000 Units 60 minutes later
`* One Unit is equal to the mean C1 inhibitor concentration of 1 mL of normal
`human plasma
`The maximum plasma concentrations (Cmax) and area under the plasma concentration-
`time curve (AUC) increased from the single to double dose, although the increase was
`not dose proportional. The mean half-lives of CINRYZE were 56 hours (range 11 to
`108 hours) for a single dose and 62 hours (range 16 to 152 hours) for the double dose.
`Studies have not been conducted to evaluate the PK of CINRYZE in special patient
`populations identified by gender, race, age (pediatric or geriatric), or the presence of
`renal or hepatic impairment.
`13 NONCLINICAL TOXICOLOGY
`13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
`No animal studies have been completed to evaluate the effects of CINRYZE on
`carcinogenesis, mutagenesis, and impairment of fertility.
`13.2 Animal Toxicology and/or Pharmacology
`Acute toxicity of CINRYZE was studied in a combined acute toxicity and 7-day repeat
`dose/ dose range finding (DRF) study in Sprague Dawley rats. Repeat dose toxicity
`was studied in a 7-day repeat dose follow up to the acute dose study. The acute and
`repeated dose toxicity studies were performed with intravenous administration of
`CINRYZE at dose levels of 1, 7, and 28 times normal dose. No signs of toxicity were
`observed in the single dose study. In the repeated dose study, no signs of toxicity
`were observed in the two lower doses. Repeat dosing in the rat resulted in a robust
`neutralizing antibody response between days 1 and 14. Therefore, toxicity in animals
`dosed repeatedly is difficult to interpret.
`In vitro and in vivo thrombogenicity studies showed a potential for clot formation
`when CINRYZE was administered at doses 14 times the recommended clinical dose
`(greater than 200U/kg).
`14 CLINICAL STUDIES
`The safety and efficacy of CINRYZE prophylaxis therapy to reduce the incidence,
`severity, and duration of HAE attacks was demonstrated in a single randomized, double
`blind, placebo controlled multi-center cross-over study of 24 patients. Patients were
`screened to confirm a diagnosis of HAE and a history of at least two HAE attacks
`per month. 24 patients (mean age 38.1 years with a range of 9 to 73 years) were
`randomized to one of two treatment groups: either CINRYZE prophylaxis for 12 weeks
`followed by 12 weeks of placebo prophylaxis; or randomized to placebo prophylaxis
`for 12 weeks followed by 12 weeks of CINRYZE prophylaxis. Two subjects dropped
`out (one in each arm); 22 patients crossed over into period 2 and were included in the
`efficacy analysis. Patients were given blinded injections (CINRYZE or placebo) every
`3 to 4 days, approximately 2 times per week. Patients recorded all angioedema
`symptoms daily. An attack was defined as the subject-reported indication of swelling at
`any location following a report of no swelling on the previous day.
`The efficacy determination was based on the number of attacks during the 12-week period
`while receiving CINRYZE as compared to the number of attacks during the placebo
`treatment period. The effectiveness of C1 esterase inhibitor prophylaxis in reducing
`the number of HAE attacks was variable among the subjects as shown in table 6:
`Table 6 The Randomized, Placebo-Controlled, Crossover, Routine Prophylaxis
`Trial: Prevention of HAE Attacks Clinical Trial Results by Subject
`Percent Reduction
`Subject
`in Attack Frequency
`1
`100%
`2
`100%
`3
`100%
`4
`100%
`5
`90%
`6
`88%
`7
`84%
`8
`83%
`9
`78%
`10
`76%
`11
`60%
`12
`47%
`13
`43%
`14
`43%
`15
`32%
`16
`31%
`17
`25%
`18
`21%
`19
`10%
`20
`1%
`21
`-8%
`22
`-85%
`Table 7 Summary Statistics on Number of HAE Attacks in the Randomized,
`Placebo-Controlled, Crossover, Routine Prophylaxis Trial
`Statistic
`CINRYZE N=22
`Placebo N=22
`Mean
`6.1
`12.7
`SD
`5.4
`4.8
`Median
`6
`13.5
`Min
`0
`6
`Max
`17
`22
`GEE Analysis Results
`
`Number
`of Attacks
`
`p-value
`Effect Assessed
`<0.0001
`Treatment Effect
`0.3347
`Sequence Effect
`0.3494
`Period Effect
`Patients treated with CINRYZE had a 66% reduction in days of swelling (p<0.0001),
`and decreases in the average severity of attacks (p=0.0006) and the average duration
`of attacks (p=0.0023), as shown in table 8.
`Table 8 The Randomized, Placebo-Controlled, Crossover, Routine
` Prophylaxis Trial: Secondary Efficacy Outcomes
`
`CINRYZE
`N=22
`
`Placebo
`N=22
`
`1.3 (0.85)
`
`1 9 (0.36)
`
`95% Confidence
`Interval for
`Treatment Effect
`(Placebo minus
`CINRYZE)
`0.58**
`(0.19, 0.97)
`
`1.23**
`(0.49, 1.96)
`19.5**
`(11.94, 27.06)
`
`2.1 (1.13)
`
`3.4 (1.4)
`
`10.1 (10.73)
`
`29.6 (16.9)
`
`Mean Severity of
`HAE Attacks (Score
`from 1 to 3)1 (SD)
`Mean Duration of
`HAE Attacks (Days)
`(SD)
`Days of Swelling
`(SD)
`1 1=mild; 2=moderate; and 3=severe
`**p<0.01
`15 REFERENCES
`1. Davis AE, The pathophysiology of hereditary angioedema. Clin Immunol. 2005;
`114:3-9.
`2. Arzneimittelkommission der Deutschen Aertzteschaft. Schwerwiegende
`Thrombenbildung nach Berinert HS. Dtsch Aerztebl. 2000; 97:B-864
`3. Horstick, G et al, 2001. Circulation 104:3125-3131
`16 HOW SUPPLIED/STORAGE AND HANDLING
`• CINRYZE is a lyophilized powder that is supplied in a vacuum-sealed single-use
`glass vial that contains 500 Units per vial to be reconstituted with 5 mL Sterile
`Water for Injection, USP (Not supplied). It is packaged for sale, and is stable for the
`period stated on the vial and carton label when stored at 2 C -25 C (36 F-77 F).
`• Do not freeze.
`• Store the vial in the original carton to protect it from light.
`• Do not use beyond the expiration date on the vial of CINRYZE.
`• NDC Number for the Carton and Vial: NDC 42227-081-05.
`
`17 PATIENT COUNSELING INFORMATION
`Inform patients to immediately report the following to their physician:
`•Signs of allergic-type hypersensitivity reactions including hives (itchy white
`elevated patches), tightness of the chest, wheezing, hypotension and anaphylaxis
`[5 1]. Advise patients to discontinue use of CINRYZE and contact their physicians
`if these symptoms occur.
`Advise female patients to notify their physician if they become pregnant or intend
`to become pregnant during their routine prevention with CINRYZE.
`Advise patients to notify their physician if they are breastfeeding or plan
`to breastfeed.
`Based on their current regimen, advise patients to bring an adequate supply
`of CINRYZE for routine prevention when traveling.
`Advise patient that, because CINRYZE is made from human blood, it may carry
`a risk of transmitting infectious agents, e.g. viruses, and, theoretically, the
`Creutzfeldt-Jakob disease (CJD) agent [5.3, 11]. The risk of transmitting
`disease has been reduced, but not eliminated, by carefully selecting blood donors,
`testing donors for infections, and inactivating or removing most viruses during the
`manufacturing process. Inform patients of the risks and benefits of CINRYZE before
`prescribing or administering to the patient.
`FDA-Approved Patient Labeling
`Information for the Patient
`CINRYZE® (SIN-rise)
`(C1 Esterase Inhibitor [Human])
`This leaflet summarizes important information about CINRYZE. Please read it
`carefully before using CINRYZE and each time you get a refill. There may be new
`information. This information does not take the place of talking with your healthcare
`provider, and it does not include all of the important information about CINRYZE.
`If you have any questions after reading this, ask your healthcare provider.
`Do not attempt to self-administer unless you have been taught how by your
`healthcare provider.
`What is CINRYZE?
`CINRYZE is an injectable medicine that is used to help prevent swelling and/or
`painful attacks in teenagers and adults with Hereditary Angioedema (HAE). HAE is
`caused by the decreased functioning of a protein called C1 esterase inhibitor that is
`present in your blood and helps control inflammation (swelling) and parts of the
`immune system. CINRYZE contains C1 esterase inhibitor. Before you can inject
`CINRYZE into your vein (intravenous injection), you must dissolve the CINRYZE
`powder using Sterile Water for Injection, USP. You can get supplies, including
`Sterile Water for Injection, USP from your pharmacist.
`Who should not use CINRYZE?
`You should not use CINRYZE if you have had life-threatening immediate
`hypersensitivity reactions, including anaphylaxis to the product.
`What should I tell my healthcare provider before using CINRYZE?
`Tell your healthcare provider about all of your medical conditions, including if you
`• are pregnant or planning to become pregnant. It is not known if CINRYZE can
`harm your unborn baby.
`• are breastfeeding or plan to breastfeed. It is not known if CINRYZE passes into
`your milk and if it can harm your baby.
`• have a history of blood clotting problems. Very high doses of C1 esterase inhibitor
`could increase the risk of blood clots.
`Tell your healthcare provider and pharmacist about all of the medicines you take,
`including all prescription and non-prescription medicines such as over-the-counter
`medicines, supplements, or herbal remedies.
`What are the possible side effects of CINRYZE?
`Allergic reactions

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket